WZ-1831
WZ-1831 is a selective inhibitor of the constitutive proteasome β5c subunit (IC50 0.01 μM). WZ-1831 exhibits anticancer activity against multiple myeloma. WZ-1831 synergizes with the β5i-selective inhibitor PKS21265 to induce cytotoxicity. WZ-1831 can be used for research on multiple myeloma.
For research use only. We do not sell to patients.
- CAS No.: 2892822-24-9
- Formula: C25H29BN4O6
- Molecular Weight:492.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MM1.S | EC50 |
0.14 μM
|
Cytotoxicity against human multiple myeloma MM.1S cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
Cytotoxicity against human multiple myeloma MM.1S cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
|
36608337 |
| RPMI-8226 | EC50 |
2.9 μM
|
Cytotoxicity against human multiple myeloma RPMI8226 cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
Cytotoxicity against human multiple myeloma RPMI8226 cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
|
36608337 |
| HepG2 | EC50 |
45 μM
|
Cytotoxicity against human liver hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
Cytotoxicity against human liver hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Cell-titer/Glo assay.
|
36608337 |
| PBMC | EC50 |
>50 μM
|
Cytotoxicity against human peripheral blood mononuclear cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay.
Cytotoxicity against human peripheral blood mononuclear cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay.
|
36608337 |
In Vitro
WZ-1831 (11.1-100 μM) is specific for proteasome inhibition and does not inhibit cathepsin L, trypsin, or chymotrypsin at concentrations up to 100 μM[1].
WZ-1831 (72 h) is not cytotoxic to peripheral blood mononuclear cells (PBMCs), with an EC50 > 50 μM after 72 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MM.1S and RPMI8226 cells
-
Concentration:Various concentrations
-
Incubation Time:72 h
-
Result:In the presence of β5i-selective inhibitor PKS21265, the EC50 of WZ-1831 was shifted by 6-fold against MM.1S cells and by 10-fold against RPMI8226 cells.
Chemical Information
-
CAS No. 2892822-24-9
-
Molecular Weight 492.33
-
Formula C25H29BN4O6
-
SMILES
OB(O)C1=CC=CC(CNC([C@H](CC(NC(C)(C)C)=O)NC(C(C2=CNC3=CC=CC=C23)=O)=O)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Zhan W, et al. Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit. Journal of medicinal chemistry. 2023 Jan 26;66(2):1172-1185. [Content Brief]
[2]. Laurent P, et al. The immunoproteasome regulates ILC2 responses by modulating mitochondrial capacity. Proceedings of the National Academy of Sciences of the United States of America. 2025 Nov 25;122(47):e2518190122. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WZ-1831 Related Classifications
HY-189134 Related Classifications
Powered by Bioz